Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (80 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,355 records in scope (CR5), not by the ranked leaders only.
This landscape covers 1,355 patent families published between 2015 and mid-2026 that combine stapled-peptide or hydrocarbon-staple claim language with functional claims around alpha helicity, protease resistance, cell uptake, staple positioning, membrane lysis risk or target interface coverage. The scope is deliberately narrow: it captures work that treats the peptide staple as a functional design variable, not every macrocyclic peptide filing in the broader field.
Records concentrate around therapeutic peptide chemistry rather than diagnostic or agricultural use, and receiving-office data shows the United States, Europe and the WIPO PCT route carrying the bulk of filings, with Australia, Canada and Israel forming a secondary tier of national-phase entries.
Pick a task. Every answer cites the patents behind it.
Two views of the same 1,355-record dataset: publication volume by year, and the IPC subclasses those records are tagged with.
Annual publications rose from 74 in 2017 to a peak of 80 in 2021, then declined to 45 by 2024 — a 44% drop across that three-year window. Counts for 2025 and 2026 are not yet comparable, since publication typically lags filing by around 18 months and those years are still being backfilled.
A61K (medicinal preparations) and C07K (peptides and proteins) each cover more than two-thirds of records, confirming this is primarily a therapeutic-chemistry field. A61P (therapeutic activity) appears on over a third of records, while analytical (G01N), genetic-engineering (C12N), enzyme/DNA measurement (C12Q), agrochemical (A01N) and condensation-polymer (C08G) classes each sit under 8%, marking them as secondary or emerging claim territory rather than core ground.
Shares are the percentage of the 1,355 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about stapled and constrained peptides and every answer comes back with the patent numbers behind it.
Try EurekaThe disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.Filed as US20210061856A1, assigned to Dana-Farber Cancer Institute, Inc., published 2021-03-04.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2009155258A2 | Glucagon/GLP-1 receptor co-agonists | 426 |
| 2 | WO2011075393A2 | Glucagon/GLP-1 receptor co-agonists | 293 |
| 3 | US20050250680A1 | Stabilized alpha helical peptides and uses thereof | 291 |
| 4 | WO2005044839A2 | Stabilized alpha helical peptides and uses thereof | 262 |
| 5 | WO2010148089A1 | GIP receptor-active glucagon compounds | 255 |
| 6 | WO2011094337A1 | Glucagon antagonist - GIP agonist conjugates and compositions for the treatment of metabolic disorders and ob… | 231 |
| 7 | WO2009099763A1 | Ester-based peptide prodrugs | 229 |
| 8 | WO2010071807A1 | Amide based glucagon superfamily peptide prodrugs | 202 |
| 9 | WO2012088116A2 | Glucagon analogs exhibiting GIP receptor activity | 190 |
| 10 | US7202332B2 | Methods for preparing internally constrained peptides and peptidomimetics | 172 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three patterns stand out once volume, concentration and claim composition are read together.
The top five assignees account for 1,084 of the 1,355 records in scope, and the top ten reach 88.0%. There is essentially no independent mid-tier: after the leaders, the ranking drops quickly toward single-digit filers, meaning freedom-to-operate work has to focus on a handful of portfolios rather than a broad competitive field.
Annual publications fell 44% from 80 in 2021 to 45 in 2024, the most recent year that can be read as complete. Several of the largest assignees show flat or declining recent-year output, which is consistent with a field where the core staple-chemistry claims have already been staked out rather than one that has stopped attracting interest.
A61K and C07K between them tag over two-thirds of records each, showing the dominant claim style is therapeutic composition and peptide structure. Classes tied to analytical methods, genetic engineering or agrochemical use each cover under 8% of records, which is a narrower base than the core chemistry classes and worth checking before assuming it is crowded.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stapled and constrained peptides, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Dana-Farber Cancer Institute, Inc. | President and Fellows of Harvard College | 71 |
| Indiana University Research & Technology Corporation | DIMARCHI RICHARD D | 21 |
| Indiana University Research & Technology Corporation | F. Hoffmann-La Roche Ltd | 20 |
| Dana-Farber Cancer Institute, Inc. | WALENSKY LOREN D | 13 |
| DIMARCHI RICHARD D | SMILEY DAVID L | 12 |
| Indiana University Research & Technology Corporation | Novo Nordisk A/S | 10 |
| Aileron Therapeutics, Inc. | NASH HUW M | 10 |
| WALENSKY LOREN D | BIRD GREGORY H | 10 |
Ten co-assignee pairs appear in the data, and the strongest single pairing accounts for 71 shared records — evidence that a handful of academic-industry relationships, not broad cross-licensing, structured much of the earliest claim territory.
The leader board is short and steep; most of the technical variety in this field lives outside the top ranks.
The leading assignee's 433 records dwarf the fifth-place holder's 45, an order-of-magnitude gap that is unusual even for concentrated pharma patent fields. Recent-year momentum data shows this assignee still filing, albeit at a reduced pace year over year, so the position is being defended rather than abandoned.
The strongest co-assignee relationship in the dataset links two academic and research institutions across 71 shared records, with a second pairing involving an individual inventor and a university technology-transfer office reaching 21. This points to foundational staple-chemistry IP originating in academic labs before later commercial licensing.
Beyond the top ten assignees, who together already hold 88.0% of all 1,355 records, the remaining ranked companies each contribute small counts. That long tail is where niche applications — delivery mechanisms, non-oncology indications, agrochemical uses — tend to surface, even though none of them yet rival the leaders' volume.
| Assignee | Recent year | YoY |
|---|---|---|
| Dana-Farber Cancer Institute, Inc. | 3 | -70% |
| Indiana University Research & Technology Corporation | 0 | — |
| Aileron Therapeutics, Inc. | 0 | — |
| President and Fellows of Harvard College | 0 | -100% |
| SPITFIRE PHARMA LLC | 0 | -100% |
| DIMARCHI RICHARD D | 0 | — |
| WALENSKY LOREN D | 0 | — |
| University of Chicago | 0 | -100% |
The landscape narrows down to specific questions once a filing or freedom-to-operate decision is on the table.
With one assignee holding 433 of 1,355 records, any new filing in core staple chemistry should be checked against that portfolio's claim scope before drafting begins.
Run a claim comparison in EurekaClasses like G01N, C12N and C08G sit under 8% of records each; monitoring new filings there flags whether the white space is closing.
Set up monitoring in EurekaTen identified co-assignee pairs, including one at 71 shared records, suggest existing academic-industry licensing structures worth understanding before approaching a target.
Explore assignee networks in EurekaOne assignee leads the field with 433 of the 1,355 records in scope, far ahead of the fifth-place holder at 45. The top five assignees combined hold 80.0% of all records, and the top ten hold 88.0%, so the field is dominated by a small number of institutional and corporate portfolios rather than spread across many competitors. Anyone assessing freedom to operate should focus diligence on this small group first, since the long tail beyond the top ten contributes comparatively little volume individually.
Publication volume peaked at 80 records in 2021 and had fallen to 45 by 2024, a 44% decline over that span, which is the most recent year the data can treat as complete. That does not necessarily mean underlying research activity is shrinking — publication typically lags filing by about 18 months, so 2025 and 2026 figures are still filling in. The safer reading is that the core hydrocarbon-staple chemistry claims were staked out early, and filing has since moderated from its peak rather than accelerating further.
US20210061856A1, assigned to Dana-Farber Cancer Institute, Inc. and published 2021-03-04, covers cell-permeable stabilized peptide modules and methods for using them to deliver cargoes into cells. It sits within the broader cell-uptake and membrane-permeability claim territory that is well represented across this dataset's A61K and C07K classes. Because it comes from one of the field's most active assignees, any delivery-mechanism work using stapled or stabilized helical peptides should be checked against its specific claim language.
IPC classes tied to analytical testing (G01N, 7.1% of records), genetic engineering (C12N, 4.5%), enzyme or DNA measurement (C12Q, 1.7%), agrochemical use (A01N, 1.4%) and condensation-polymer linker chemistry (C08G, 1.3%) all sit well below the dominant A61K and C07K classes. These lower shares suggest lighter claim density in those directions relative to core therapeutic peptide chemistry, though a low share is not proof of open space on its own and should be checked against specific competitor filings before relying on it.
Both appear prominently, and several of the strongest relationships in the data are co-assignee pairings between academic institutions and individual inventors or corporate licensees, including one pairing that spans 71 shared records. This pattern is consistent with a field where foundational staple-chemistry inventions originated in university labs before licensing or joint filing with commercial partners. It suggests that engaging with academic technology-transfer offices, not just corporate assignees, is relevant to understanding the ownership landscape.
Go past this page: query the whole stapled and constrained peptides corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page